Histology of the primary tumor correlates with false positivity of integrated 18F-FDG-PET/CT lymph node staging in resectable lung cancer patients

• Verfasst von: Damirov, Fuad [VerfasserIn]
• Verfasst von: Stoleriu, Mircea Gabriel [VerfasserIn]
• Verfasst von: Manapov, Farkhad [VerfasserIn]
• Verfasst von: Büsing, Karen-Anett [VerfasserIn]
• Verfasst von: Michels-Zetsche, Julia D. [VerfasserIn]
• Verfasst von: Preissler, Gerhard [VerfasserIn]
• Verfasst von: Hatz, Rudolf A. [VerfasserIn]
• Verfasst von: Hohenberger, Peter [VerfasserIn]
• Verfasst von: Rößner, Eric [VerfasserIn]
• Titel: Histology of the primary tumor correlates with false positivity of integrated 18F-FDG-PET/CT lymph node staging in resectable lung cancer patients
• Verf.angabe: Fuad Damirov, Mircea Gabriel Stoleriu, Farkhad Manapov, Karen Büsing, Julia Dorothea Michels, Gerhard Preissler, Rudolf A. Hatz, Peter Hohenberger and Eric D. Roessner
• Jahr: 2023
• Umfang: 14 S.
• Fussnoten: Veröffentlicht: 29. Mai 2023 ; Gesehen am 26.07.2023
• Titel Quelle: Enthalten in: Diagnostics
• Ort Quelle: Basel : MDPI, 2011
• Jahr Quelle: 2023
• Band/Heft Quelle: 13(2023), 11, Artikel-ID 1893, Seite 1-14
• ISSN Quelle: 2075-4418
• DOI: doi:10.3390/diagnostics13111893
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: 18F-FDG-PET/CT
• Sach-SW: decision tree
• Sach-SW: diagnostic accuracy
• Sach-SW: false-positive lymph nodes
• Sach-SW: lung cancer
• Sach-SW: lymph node staging
• K10plus-PPN: 185364739X

Abstract

This study aimed to evaluate the diagnostic accuracy and false positivity rate of lymph node (LN) staging assessed by integrated 18F-fluorodeoxyglucose positron emission computed tomography (18F-FDG-PET/CT) in patients with operable lung cancer to the tumor histology. In total, 129 consecutive patients with non-small-cell lung cancer (NSCLC) undergoing anatomical lung resections were included. Preoperative LN staging was evaluated in the relationship to the histology of the resected specimens (group 1: lung adenocarcinoma/LUAD; group 2: squamous cell carcinoma/SQCA). Statistical analysis was performed by the Mann-Whitney U-test, the chi2 test, and binary logistic regression analysis. To establish an easy-to-use algorithm for the identification of LN false positivity, a decision tree including clinically meaningful parameters was generated. In total, 77 (59.7%) and 52 (40.3%) patients were included in the LUAD and SQCA groups, respectively. SQCA histology, non-G1 tumors, and tumor SUVmax > 12.65 were identified as independent predictors of LN false positivity in the preoperative staging. The corresponding ORs and their 95% CIs were 3.35 [1.10-10.22], p = 0.0339; 4.60 [1.06-19.94], p = 0.0412; and 2.76 [1.01-7.55], and p = 0.0483. The preoperative identification of false-positive LNs is an important aspect of the treatment regimen for patients with operable lung cancer; thus, these preliminary findings should be further evaluated in larger patient cohorts.